FULGENT GENETICS, INC. Contract Liability (Deferred Revenue)
FULGENT GENETICS, INC. (FLGT) had Contract Liability (Deferred Revenue) of $3.40 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-07-30
- 2026-06-30: Contract with Customer, Liability, Current $3.40M.
- 2026-03-31: Contract with Customer, Liability, Current $3.01M.
- 2025-12-31: Contract with Customer, Liability, Current $3.63M.
- 2025-09-30: Contract with Customer, Liability, Current $2.31M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $3.40M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $3.01M 10-Q · filed 2026-05-01 |
| 2025-12-31 | $3.63M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $2.31M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $2.67M 10-Q · filed 2025-08-01 |
| 2025-03-31 | $2.82M 10-Q · filed 2025-05-02 |
| 2024-12-31 | $2.23M 10-K · filed 2026-02-27 |
| 2024-09-30 | $2.97M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $2.74M 10-Q · filed 2024-08-02 |
| 2024-03-31 | $2.76M 10-Q · filed 2024-05-03 |
| 2023-12-31 | $2.87M 10-K · filed 2025-02-28 |
| 2023-09-30 | $2.59M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $2.60M 10-Q · filed 2023-08-04 |
| 2023-03-31 | $2.73M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $3.20M 10-K · filed 2024-02-28 |
| 2022-09-30 | $2.60M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $10.10M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $14.10M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $14.57M 10-K · filed 2023-02-28 |
| 2021-09-30 | $7.88M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $6.92M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $13.96M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $26.58M 10-K · filed 2022-02-28 |
| 2020-09-30 | $18.46M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $622.00K 10-Q · filed 2020-08-05 |
| 2020-03-31 | $444.00K 10-Q · filed 2020-05-06 |
| 2019-12-31 | $365.00K 10-K · filed 2021-03-08 |
| 2018-12-31 | $166.00K 10-K · filed 2020-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |